GlaxoSmithKline plc (GSK) Earns “Buy” Rating from Citigroup Inc.
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reaffirmed by analysts at Citigroup Inc. in a research note issued on Wednesday. They presently have a GBX 1,800 ($23.50) price target on the stock. Citigroup Inc.’s price target would suggest a potential upside of 5.32% from the company’s previous close.
Several other research analysts also recently commented on GSK. BNP Paribas reissued a “neutral” rating and set a GBX 1,560 ($20.36) price objective on shares of GlaxoSmithKline plc in a report on Thursday, August 4th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a report on Tuesday, July 19th. Liberum Capital reissued a “buy” rating and set a GBX 1,900 ($24.80) price objective on shares of GlaxoSmithKline plc in a report on Tuesday, September 20th. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,800 ($23.50) price objective on shares of GlaxoSmithKline plc in a report on Friday, September 2nd. Finally, Sanford C. Bernstein set a GBX 1,755 ($22.91) price objective on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a report on Thursday, July 28th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of GBX 1,682.13 ($21.96).
Shares of GlaxoSmithKline plc (LON:GSK) traded up 1.70% on Wednesday, reaching GBX 1709.00. The company had a trading volume of 8,905,847 shares. The firm’s market capitalization is GBX 83.07 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,716.50. The stock’s 50 day moving average is GBX 1,645.03 and its 200 day moving average is GBX 1,551.57.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/glaxosmithkline-plc-gsk-earns-buy-rating-from-citigroup-inc-3.html
The company also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.
In related news, insider Slaoui,Moncef acquired 28 shares of the stock in a transaction dated Friday, August 12th. The stock was acquired at an average cost of GBX 2,208 ($28.82) per share, for a total transaction of £618.24 ($807.00). Also, insider Witty,Sir Andrew P sold 10,000 shares of GlaxoSmithKline plc stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total transaction of £169,300 ($220,989.43).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.